LASTING RELIEF THAT
CAN START AS
EARLY AS 2 WEEKS1*

Xiidra reduced symptoms of eye dryness at
2 weeks in 2 out of 4 studies, with improvements
observed at 6 and 12 weeks in all 4 studies1

See more study details below

*In some patients with continued daily use. One drop in each eye, twice daily (approximately 12 hours apart).1

EDS was rated by patients using a visual analogue scale (0=no discomfort, 100=maximal discomfort) at each study visit. The average baseline EDS was between 40 and 70.1

Mean percent change from baseline in EDS over 12 weeks1

SD=standard deviation; vehicle=placebo.

Indicates relative difference compared to vehicle.

SD=standard deviation; vehicle=placebo.

Indicates relative difference compared to vehicle.

SD=standard deviation; vehicle=placebo.

Indicates relative difference compared to vehicle.

SD=standard deviation; vehicle=placebo.

Indicates relative difference compared to vehicle.

Based on analysis of covariance (ANCOVA) model adjusted for baseline value in Study 1, and ANCOVA model adjusted for baseline value and randomization stratification factors in Studies 2-4. All randomized and treated patients were included in the analysis and missing data were imputed using last-available data. In Study 1, one Xiidra-treated subject who did not have a baseline value was excluded from analysis.1

The safety and efficacy of Xiidra were assessed in four 12-week, randomized, multicenter, double-masked, vehicle-controlled studies (N=2133). Patients were dosed twice daily. The mean age was 59 years (range, 19-97 years). The majority of patients were female (76%). Use of artificial tears was not allowed during the studies. The study end points included assessment of signs (based on Inferior fluorescein Corneal Staining Score [ICSS] on a scale of 0 to 4) and symptoms (based on patient-reported EDS on a visual analogue scale of 0 to 100).1

Help your appropriate patients diagnosed with dry
eye
disease find fast and lasting
symptom relief
with Xiidra.1

Indication

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

Important Safety Information

Click here for Full Prescribing Information.

Reference

  1. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; June 2020.